Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SGMO 
Sangamo Therapeutics Inc (SGMO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: SGMO (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.1
1 Year Target Price $4.1
| 3 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 59.1% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 152.33M USD | Price to earnings Ratio - | 1Y Target Price 4.1 |
Price to earnings Ratio - | 1Y Target Price 4.1 | ||
Volume (30-day avg) 7 | Beta 1.21 | 52 Weeks Range 0.41 - 3.18 | Updated Date 09/15/2025 |
52 Weeks Range 0.41 - 3.18 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -77.48% | Operating Margin (TTM) -97.54% |
Management Effectiveness
Return on Assets (TTM) -41.15% | Return on Equity (TTM) -292.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 137450118 | Price to Sales(TTM) 1.86 |
Enterprise Value 137450118 | Price to Sales(TTM) 1.86 | ||
Enterprise Value to Revenue 1.68 | Enterprise Value to EBITDA -1 | Shares Outstanding 301708992 | Shares Floating 295141270 |
Shares Outstanding 301708992 | Shares Floating 295141270 | ||
Percent Insiders 2.16 | Percent Institutions 16.96 |
Upturn AI SWOT
Sangamo Therapeutics Inc
Company Overview
History and Background
Sangamo Therapeutics, Inc. was founded in 1995. It pioneered the development of zinc finger nuclease (ZFN) technology for gene editing. Initially focused on HIV, it has expanded into multiple therapeutic areas using gene editing and gene therapy.
Core Business Areas
- Gene Therapy: Developing adeno-associated virus (AAV) based gene therapies for diseases where a functional copy of a gene can restore normal cellular function. Includes programs in neurology and immunology.
- Gene Editing: Utilizing zinc finger nucleases (ZFNs) and other technologies to precisely edit DNA sequences in vivo or ex vivo. Focus areas include hematology and oncology.
- Cell Therapy: Utilizing engineered cell therapy for various diseases.
Leadership and Structure
Sangamo is led by a management team with experience in gene editing and therapy. The organizational structure includes research, clinical development, manufacturing, and commercial functions.
Top Products and Market Share
Key Offerings
- Giroctocogene Fitelparvovec (Roctavian): A gene therapy for severe hemophilia A. Roctavian is partnered with BioMarin Pharmaceutical. FDA approved for severe hemophilia A, market share and revenue still building. Competitors: Hemlibra (Roche), gene therapies from other companies such as CSL Behring.
- ST-920: A gene therapy in development for Fabry disease. Competitors: Enzyme replacement therapies and other investigational gene therapies from companies like AVROBIO.
Market Dynamics
Industry Overview
The gene editing and gene therapy market is rapidly growing, driven by advancements in technology and increasing regulatory support. The market is competitive, with many companies developing novel therapies for a range of diseases.
Positioning
Sangamo is a pioneer in gene editing, holding key intellectual property around zinc finger nucleases. They are working to advance several clinical programs, but face competition from other gene editing and gene therapy companies.
Total Addressable Market (TAM)
The total addressable market for gene editing and gene therapy is projected to reach billions of dollars in the coming years. Sangamo is positioned to capture a share of this market with its pipeline of programs, focusing on areas with unmet medical need.
Upturn SWOT Analysis
Strengths
- Pioneering gene editing technology (ZFN)
- Experienced leadership team
- Partnership with BioMarin for Roctavian
- Diverse pipeline of gene therapy and gene editing programs
Weaknesses
- High cash burn rate
- Clinical trial risks
- Competition from other gene editing companies
- Dependence on partnerships for commercialization
Opportunities
- Expanding pipeline into new therapeutic areas
- Potential for regulatory approvals
- Strategic partnerships
- Technological advancements in gene editing
Threats
- Regulatory hurdles
- Clinical trial failures
- Competition from established pharmaceutical companies
- Ethical concerns surrounding gene editing
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- BEAM
- BMRA
Competitive Landscape
Sangamo faces competition from other gene editing companies. Sangamo's strengths lie in its ZFN technology, but it must compete against CRISPR and base editing technologies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been marked by technological advancements and clinical trial progress.
Future Projections: Future projections are dependent on clinical trial outcomes, regulatory approvals, and partnerships.
Recent Initiatives: Recent strategic initiatives include focusing on core programs and partnerships.
Summary
Sangamo Therapeutics is a pioneering gene editing company with both potential and significant risks. The company's expertise in ZFN technology, partnered with BioMarin, is a strength, but it faces strong competition and clinical trial uncertainties. Success hinges on advancing its pipeline and navigating the complex regulatory landscape. Investors should monitor financial performance and progress in clinical trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sangamo Therapeutics Inc
Exchange NASDAQ | Headquaters Richmond, CA, United States | ||
IPO Launch date 2000-04-06 | CEO, President & Director Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 183 | Website https://www.sangamo.com |
Full time employees 183 | Website https://www.sangamo.com | ||
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.